BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sinagra E, Perricone G, D’Amico M, Tinè F, D’Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39:557-568. [PMID: 24461301 DOI: 10.1111/apt.12634] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Abid S, Ali S, Baig MA, Waheed AA. Is it time to replace propranolol with carvedilol for portal hypertension? World J Gastrointest Endosc 2015; 7(5): 532-539 [PMID: 25992192 DOI: 10.4253/wjge.v7.i5.532] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017;66:849-859. [PMID: 27864004 DOI: 10.1016/j.jhep.2016.11.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 12.3] [Reference Citation Analysis]
3 Wei ZG, Wei FX, Shao ZW, Su GH, Qi XP, Zhang YC. Lowering hepatic venous pressure agent carvedilol versus variceal banding ligation for clinical outcomes of cirrhotic portal hypertension. Ther Clin Risk Manag 2019;15:45-57. [PMID: 30636878 DOI: 10.2147/TCRM.S184863] [Reference Citation Analysis]
4 García-Pagán JC, Bosch J, Trebicka J, Abraldes JG, Albillos A, Grønbaek H, Giráldez Á, Zipprich A, Bureau C, Hernández-Gea V; International Variceal Bleeding Observational Study Group, Baveno Cooperation. Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. Aliment Pharmacol Ther 2020;52:927-8. [PMID: 32852811 DOI: 10.1111/apt.15926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746 [PMID: 34367495 DOI: 10.4254/wjh.v13.i7.731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
6 Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rössle M, Panther E, Wiest R, Caca K, Hoffmeister A, Lutz H, Schoo R, Lorenzen H, Trebicka J, Appenrodt B, Schepke M, Fimmers R; German Study Group for Prophylaxis of Variceal Rebleeding. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology 2015;149:660-8.e1. [PMID: 25989386 DOI: 10.1053/j.gastro.2015.05.011] [Cited by in Crossref: 123] [Cited by in F6Publishing: 92] [Article Influence: 17.6] [Reference Citation Analysis]
7 Jha S, Saharawat K, Keshari R, Jha P, Purkayastha S, Ranjan R. Addition of Simvastatin to Carvedilol and Endoscopic Variceal Ligation improves rebleeding and survival in patients with Child-Pugh A and B class but not in Child Pugh C class. Ann Clin Gastroenterol Hepatol 2019;3:020-6. [DOI: 10.29328/journal.acgh.1001010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Stanley AJ, Dickson S, Hayes PC, Forrest EH, Mills PR, Tripathi D, Leithead JA, MacBeth K, Smith L, Gaya DR, Suzuki H, Young D. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol. 2014;61:1014-1019. [PMID: 24953021 DOI: 10.1016/j.jhep.2014.06.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
9 Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018;47:1162-1169. [PMID: 29492989 DOI: 10.1111/apt.14576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
10 Razafindrazoto CI, Razafindrabekoto LDE, Hasina Laingonirina DH, Raveloson R, Rasolonjatovo AS, Rakotozafindrabe ALR, Rabenjanahary TH, Razafimahefa SH, Ramanampamonjy RM. Carvedilol versus propranolol in the prevention of variceal rebleeding in hepatosplenic schistosomiasis: Efficacy and safety. JGH Open. [DOI: 10.1002/jgh3.12721] [Reference Citation Analysis]
11 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Role of band ligation for secondary prophylaxis of variceal bleeding. World J Gastroenterol 2018;24:2902-14. [PMID: 30018485 DOI: 10.3748/wjg.v24.i26.2902] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310-35. [PMID: 27786365 DOI: 10.1002/hep.28906] [Cited by in Crossref: 918] [Cited by in F6Publishing: 722] [Article Influence: 183.6] [Reference Citation Analysis]
13 Bosch J. Portal Hypertension and Cirrhosis: From Evolving Concepts to Better Therapies. Clin Liver Dis (Hoboken) 2020;15:S8-S12. [PMID: 32140209 DOI: 10.1002/cld.844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs 2016;21:167-81. [PMID: 27148904 DOI: 10.1080/14728214.2016.1184647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
15 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham HA, Zhou Y, Li J, Zhang X, Xu H, Taner CB, Yang L, Tao C. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther 2021;54:481-92. [PMID: 34224163 DOI: 10.1111/apt.16490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
17 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
18 Magaz M, Baiges A, Hernández-Gea V. Precision medicine in variceal bleeding: Are we there yet? J Hepatol. 2020;72:774-784. [PMID: 31981725 DOI: 10.1016/j.jhep.2020.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Burza MA, Marschall HU, Napoleone L, Molinaro A. The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight? Pharmacol Res 2017;119:20-6. [PMID: 28099882 DOI: 10.1016/j.phrs.2017.01.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
21 Jachs M, Reiberger T. Prevention of Variceal Bleeding and Rebleeding by Nonselective Beta-Blockers: A Tailored Approach. Clin Liver Dis 2021;25:311-26. [PMID: 33838852 DOI: 10.1016/j.cld.2021.01.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Williams MJ, Hayes P. Improving the management of gastrointestinal bleeding in patients with cirrhosis. Expert Rev Gastroenterol Hepatol 2016;10:505-15. [PMID: 26581713 DOI: 10.1586/17474124.2016.1122523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
23 Diaz-Soto MP, Garcia-Tsao G. Management of varices and variceal hemorrhage in liver cirrhosis: a recent update. Therap Adv Gastroenterol 2022;15:17562848221101712. [PMID: 35757384 DOI: 10.1177/17562848221101712] [Reference Citation Analysis]
24 Rajoriya N, Tripathi D. Non-selective beta-blockers in cirrhosis: Current concepts and controversies. World J Pharmacol 2016; 5(1): 15-31 [DOI: 10.5497/wjp.v5.i1.15] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Mandorfer M, Reiberger T. Reply to: "Non selective beta blockers in cirrhosis". J Hepatol 2017;67:1343-4. [PMID: 28789883 DOI: 10.1016/j.jhep.2017.07.018] [Reference Citation Analysis]
26 Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020; 26(40): 6111-6140 [PMID: 33177789 DOI: 10.3748/wjg.v26.i40.6111] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
27 Dunne PDJ, Sinha R, Stanley AJ, Lachlan N, Ireland H, Shams A, Kasthuri R, Forrest EH, Hayes PC. Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders-Authors' reply. Aliment Pharmacol Ther 2020;52:929-30. [PMID: 32852823 DOI: 10.1111/apt.15953] [Reference Citation Analysis]
28 Hanif S, Irfan N, Danish Z, Hussain N, Ali M, Nasir B, Iqbal J, Saeed H, Ali R, Saleem Z. Computer Aided Formulation and Characterization of Propranolol Hcl Buccal Tablet Using Polymeric Blend. TOPROCJ 2017;8:1-13. [DOI: 10.2174/2210289201708011001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Bultas AC, Teshome B, Richter SK, Schafers S, Cooke E, Call WB. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications. Ann Pharmacother 2020;54:583-93. [DOI: 10.1177/1060028019893092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Miao Z, Lu J, Yan J, Lu L, Ye B, Gu M. Comparison of Therapies for Secondary Prophylaxis of Esophageal Variceal Bleeding in Cirrhosis: A Network Meta-analysis of Randomized Controlled Trials. Clin Ther 2020;42:1246-1275.e3. [PMID: 32624321 DOI: 10.1016/j.clinthera.2020.04.014] [Reference Citation Analysis]
31 Chen S, Wang JJ, Wang QQ, Hu JW, Dong S, Hu LJ, Jian YC, Liu XY, Yang GM, Xiong WJ. The effect of carvedilol and propranolol on portal hypertension in patients with cirrhosis: a meta-analysis. Patient Prefer Adherence 2015;9:961-70. [PMID: 26203230 DOI: 10.2147/PPA.S84762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
32 Pfisterer N, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, Sandrieser L, Baumann L, Riedl F, Scheiner B, Pachofszky T, Dolak W, Schrutka-Kölbl C, Ferlitsch A, Schöniger-Hekele M, Peck-Radosavljevic M, Trauner M, Madl C, Reiberger T. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther 2018;47:966-79. [PMID: 29388229 DOI: 10.1111/apt.14485] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
33 Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl. 2017;23:1058-1069. [PMID: 28590564 DOI: 10.1002/lt.24794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
34 Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 2022;55:1099-115. [PMID: 35235219 DOI: 10.1111/apt.16831] [Reference Citation Analysis]
35 Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, Peck-radosavljevic M, Ferlitsch A. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther 2018;47:86-94. [DOI: 10.1111/apt.14377] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
36 Garbuzenko DV. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol 2015; 21(20): 6117-6126 [PMID: 26034348 DOI: 10.3748/wjg.v21.i20.6117] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
37 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Reply. Hepatology 2017;66:302-3. [PMID: 28342181 DOI: 10.1002/hep.29180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
39 Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49:3-10. [PMID: 27717792 DOI: 10.1016/j.dld.2016.09.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
40 Liu J, Shi Q, Xiao S, Zhou C, Zhou B, Yuan F, Zheng C, Lin S, Qian K, Feng G, Xiong B. Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage. J Gastroenterol Hepatol 2020;35:278-83. [PMID: 31222830 DOI: 10.1111/jgh.14761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
41 Ilyas JA, Kanwal F. Primary prophylaxis of variceal bleeding. Gastroenterol Clin North Am 2014;43:783-94. [PMID: 25440925 DOI: 10.1016/j.gtc.2014.08.008] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
42 Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J; Carvedilol-IPD-MA-group, From the PREDESCI study (Ref. 7)., From the study by Shah HA et al (Ref.16)., From the study by Tripathi D et al (Ref.14)., From the study by Bhardwaj A et al (Ref.15)., Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol 2022:S0168-8278(22)00336-1. [PMID: 35661713 DOI: 10.1016/j.jhep.2022.05.021] [Reference Citation Analysis]
43 Garbuzenko DV. [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis]. Ter Arkh. 2016;88:101-108. [PMID: 27135108 DOI: 10.17116/terarkh2016888101-108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Rasool MF, Khalil F, Läer S. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. Eur J Drug Metab Pharmacokinet 2017;42:383-96. [DOI: 10.1007/s13318-016-0353-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
45 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
46 Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, Xian W, Li J, Zheng Q. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6:e010902. [PMID: 27147389 DOI: 10.1136/bmjopen-2015-010902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
47 Dwinata M, Putera DD, Adda’i MF, Hidayat PN, Hasan I. Carvedilol vs endoscopic variceal ligation for primary and secondary prevention of variceal bleeding: Systematic review and meta-analysis. World J Hepatol 2019; 11(5): 464-476 [PMID: 31183006 DOI: 10.4254/wjh.v11.i5.464] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
48 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 19.5] [Reference Citation Analysis]
49 Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf)5:113-126. [PMID: 28533909 DOI: 10.1093/gastro/gox007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
50 Kim SG, Kim TY, Sohn JH, Um SH, Seo YS, Baik SK, Kim MY, Jang JY, Jeong SW, Lee B. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. Am J Gastroenterol. 2016;111:1582-1590. [PMID: 27575713 DOI: 10.1038/ajg.2016.327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
51 Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Mohta S, Shalimar, Saraya A. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study. J Clin Exp Hepatol 2021;11:343-53. [PMID: 33994717 DOI: 10.1016/j.jceh.2020.08.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Yang J, Ge K, Chen L, Yang JL. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:1518-26. [PMID: 31094853 DOI: 10.1097/MEG.0000000000001442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Kim HY, So YH, Kim W, Ahn DW, Jung YJ, Woo H, Kim D, Kim MY, Baik SK. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol 2019;70:412-22. [PMID: 30389550 DOI: 10.1016/j.jhep.2018.10.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
55 Garcia-Tsao G, Bosch J. Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clin Gastroenterol Hepatol. 2015;13:2109-2117. [PMID: 26192141 DOI: 10.1016/j.cgh.2015.07.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
56 Seo YS. Prevention and management of gastroesophageal varices. Clin Mol Hepatol. 2018;24:20-42. [PMID: 29249128 DOI: 10.3350/cmh.2017.0064] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
57 Yoshida H, Shimizu T, Yoshioka M, Taniai N. Management of portal hypertension based on portal hemodynamics. Hepatol Res 2021;51:251-62. [PMID: 33616258 DOI: 10.1111/hepr.13614] [Reference Citation Analysis]
58 Ferrarese A, Zanetto A, Germani G, Burra P, Senzolo M. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol 2016; 8(24): 1012-1018 [PMID: 27648153 DOI: 10.4254/wjh.v8.i24.1012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
59 Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018;10:CD011510. [PMID: 30372514 DOI: 10.1002/14651858.cd011510.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
60 Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. Clin Liver Dis 2021;25:327-43. [PMID: 33838853 DOI: 10.1016/j.cld.2021.01.002] [Reference Citation Analysis]
61 Reiberger T, Bucsics T, Paternostro R, Pfisterer N, Riedl F, Mandorfer M. Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them? Curr Hepatol Rep. 2018;17:301-315. [PMID: 30546995 DOI: 10.1007/s11901-018-0420-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
62 Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. Liver Int. 2017;37 Suppl 1:104-115. [PMID: 28052623 DOI: 10.1111/liv.13277] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 7.4] [Reference Citation Analysis]
63 Baiges A, Hernández-Gea V, Bosch J. Pharmacologic prevention of variceal bleeding and rebleeding. Hepatol Int 2018;12:68-80. [PMID: 29210030 DOI: 10.1007/s12072-017-9833-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
64 Kirnake V, Arora A, Gupta V, Sharma P, Singla V, Bansal N, Goyal M, Chawlani R, Kumar A. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study. J Clin Exp Hepatol 2016;6:175-85. [PMID: 27746613 DOI: 10.1016/j.jceh.2016.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
65 Fortea JI, Puente Á, Ruiz P, Ezcurra I, Vaquero J, Cuadrado A, Arias-Loste MT, Cabezas J, Llerena S, Iruzubieta P, Rodríguez-Lope C, Huelin P, Casafont F, Fábrega E, Crespo J. Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World J Clin Cases 2018; 6(13): 611-623 [PMID: 30430116 DOI: 10.12998/wjcc.v6.i13.611] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Chen K, Wang Y, Gai X, Wang H, Li Y, Wen H, Pan W, Yang X. Design of a Time-Controlled Pulsatile Release System for Propranolol Using the Dry-Coated Method: In Vitro and In Vivo Evaluation. AAPS PharmSciTech 2017;18:2683-90. [PMID: 28281210 DOI: 10.1208/s12249-017-0746-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
67 Reiberger T, Ferlitsch A. Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Authors' reply. Aliment Pharmacol Ther 2018;47:1329-30. [PMID: 29644735 DOI: 10.1111/apt.14614] [Reference Citation Analysis]
68 Yeh WS, Yang SC, Liang CM, Li YC, Tai WC, Lee CH, Yang YH, Hsu CN, Tsai TH, Chuah SK, Wu CK. The Role of Non-Selective β-Blockers in Compensated Cirrhotic Patients without Major Complications. Medicina (Kaunas) 2019;56:E14. [PMID: 31905956 DOI: 10.3390/medicina56010014] [Reference Citation Analysis]